ASP treatment lowered the presence of sepsis risk factors in preterm infants.
Neonatal Antimicrobial Stewardship Programs (ASPs) can decrease antibiotic initiation at birth, according to a recent study published by the Pediatric Infectious Disease Journal.
Early-onset sepsis is a condition which leads to greater chances of morbidity and mortality in preterm infants. ASPs are put into place for high-risk infants to mediate the adverse effects of antibiotic exposure with the need for empiric treatment.
In the study, preterm infants with a gestational age of less than 34 weeks were reviewed 6 months after ASP was implemented. The review consisted of comparisons for the presence of perinatal sepsis risk factors, along with the effectiveness of initial empiric antibiotics treatment.
There were 479 infants involved in the study, with an average gestational age of 30 weeks and a birth weight of 1400 g.
In the pre-ASP infants, there was a 73.6% presence of sepsis risk factors, while post-ASP infants had a 68.4% presence of sepsis risk factors. Initial antibiotics were not given to 42% of infants despite risk factors, while 20% did not have perinatal sepsis risk factors and were not treated.
Investigators encouraged neonatal ASP teams to think about the dangers of antibiotic use.
Reference
Stritzke A, Tierney A, Keister F, Srivastava A, Dersch-Mills D, Hamilton C. Antimicrobialstewardship at birth in preterm infants. The Pediatric Infectious Disease Journal. 2022;41(5)394-400. doi:10.1097/INF.0000000000003462
This article originally appeared on Contemporary Pediatrics®.
Reduced subsequent births reported after severe maternal morbidity
November 26th 2024Women experiencing severe maternal morbidity during their first pregnancy face significantly lower odds of subsequent births, emphasizing the need for personalized reproductive counseling and ongoing monitoring.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More